Clinical Trial Update: Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing capecitabine to vinorelbine in high-risk breast cancer with pathologic residual tumors after preoperative chemotherapy is ongoing or not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Zhiyong Yu | Conditions: Pathologic Residual Cancer Cells | Phase 2 | Status: UNKNOWN